1Meta-Analysis2024
Anson M, Henney AE, Zhao SS, Ibarburu GH, Lip GYH, Cuthbertson DJ · Diabetes Obes Metab (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
82 peer-reviewed studies
What the evidence says
Pioglitazone (Actos) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2005–2026 with a typical study size of 5,238 participants.
Based on 82 studies · 23 meta-analyses · 51 RCTs · 33,658 total participants
Confidence
High confidenceBy outcome
34 studies in the last 5 years · Latest meta-analysis: 2026
Anson M, Henney AE, Zhao SS, Ibarburu GH, Lip GYH, Cuthbertson DJ · Diabetes Obes Metab (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Albert SG, Wood EM · Diabetes Metab Syndr (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Tran QT, Bui TT, Ngo LT, Yang BR, Baek IH, Nguyen VH · CPT Pharmacometrics Syst Pharmacol (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Lian J, Fu J · Front Endocrinol (Lausanne) (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG · Dig Liver Dis (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Liu L, Deng Y, Yang L, Wang M, Lai Y · J Diabetes Complications (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chang G, Wang J, Song J, Zhang Z, Zhang L · J Dermatolog Treat (2020)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Östlundh L, Al-Rifai RH · Adv Ther (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Alam F, Islam MA, Mohamed M, Ahmad I, Kamal MA, Donnelly R · Sci Rep (2019)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Pavlova V, Filipova E, Uzunova K, Kalinov K, Vekov T · Endocr Metab Immune Disord Drug Targets (2018)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y · Cancer Med (2018)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI · Cochrane Database Syst Rev (2020)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Sinha B, Ghosal S · Sci Rep (2020)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Zheng H, Han J · Front Endocrinol (Lausanne) (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Pereira da Silva AM, Santos do Nascimento MDV, Menegucci G, Caruso Novaes Tudella G, Silva Cabeça L, Ribeiro Gonçalves O · Alzheimer Dis Assoc Disord (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Zhang JZ, Ding Y, Xiang F, Yu SR, Zhang DZ, Guan MM · Chin Med J (Engl) (2020)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Zuo L, Wang J, Zhang N, Wang J · Curr Pharm Des (2019)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y · J Clin Endocrinol Metab (2020)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Jamialahmadi T, Mirhadi E, Reiner Ž, Abass KS, Almahmeed W, S Virani S · Curr Atheroscler Rep (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: The three drugs with the highest OR value in response were NASID (OR = 3.62(1.58, 8.32)), venlafaxin (OR = 3.50(1.83, 6.70)) and ketamine (OR = 3.28(1.89, 5.68)), while the highest OR value in remission were NASID (OR = 3.17(1.60, 6.29)), ketamine (OR = 2.99(1.58, 5.67)) and venlafaxin (OR = 2.55(1.72, 3.78)).
Yuan Z et al. · Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2020)